Figure 1 | British Journal of Cancer

Figure 1

From: Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-α in a phase III trial: final results and geographical analysis

Figure 1

(A–C) Comparison of results between MM and PMM analyses across all available post-baseline observations. MM, mixed-effects model difference between sunitinib and IFN-α; PMM, pattern-mixture model difference between sunitinib and IFN-α; FKSI-15, FACT–Kidney Symptom Index-15 item; FKSI-DRS, FKSI Disease-Related Symptoms subscale; FACT-G, Functional Assessment of Cancer Therapy–General; EQ-5D Index, EuroQoL health-utility index; EQ-VAS, EQ visual analogue scale.

Back to article page